amoxicillin; clarithromycin; vonoprazan fumarate: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Phathom	VOQUEZNA TRIPLE PAK	amoxicillin; clarithromycin; vonoprazan fumarate	CAPSULE, TABLET, TABLET;ORAL	215152	NDA	Phathom Pharmaceuticals Inc.	81520-255-14	14 BLISTER PACK in 1 CARTON (81520-255-14) / 1 KIT in 1 BLISTER PACK (81520-255-01)	2023-11-08
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 27, 2025

Introduction

The pharmaceutical landscape for antibiotics and gastrointestinal agents is robust, with a diverse array of suppliers spanning global regions. Among these, Amoxicillin, Clarithromycin, and Vonoprazan Fumarate stand out due to their widespread clinical applications. This analysis offers a comprehensive overview of the leading suppliers for these drugs, emphasizing manufacturing dominance, supply chain reliability, regulatory landscape, and market dynamics to support strategic procurement and risk management.

Amoxicillin: Global Supplier Ecosystem

Market Overview

Amoxicillin, a widely used penicillin-class antibiotic, treats bacterial infections such as respiratory tract infections, urinary tract infections, and skin infections. It is on the World Health Organization's essential medicines list, underscoring its global significance [1].

Major Suppliers

Domestic Pharmaceutical Giants:
- Pfizer Inc.: A dominant manufacturer with extensive production facilities globally. Pfizer’s Amoxicillin production adheres to strict regulatory standards, ensuring supply continuity, especially in North America and Europe.
- GlaxoSmithKline (GSK): GSK supplies Amoxicillin through various formulations, with manufacturing hubs across the UK, Spain, and India, contributing to diversified supply chains.
Asian Manufacturers:
- Aurobindo Pharma: Based in India, Aurobindo is one of the world's largest API producers for Amoxicillin, capturing significant market share due to cost advantages and manufacturing capacity.
- Hikma Pharmaceuticals: A key supplier from Jordan with a strong API portfolio and finished formulation facilities.
- Cipla Limited: Indian pharmaceutical leader with high-volume API production, supplying both domestic and export markets.
Chinese Manufacturers:
- Chinese firms such as Shanghai Pharmaceutical and North China Pharmaceutical Group produce APIs at scale, primarily for Asian markets but increasingly for exports.

Supply Considerations

Regulatory Approvals: Suppliers must meet stringent regulatory standards such as FDA, EMA, and WHO prequalification to access international markets.
Manufacturing Capacity: Facilities with large-scale API production ensure stable supply, especially critical during public health emergencies like COVID-19.
Quality Assurance: GMP adherence and robust supply chain management mitigate risks of shortages and contamination.

Clarithromycin: Leading Suppliers and Market Dynamics

Market Overview

Clarithromycin, a macrolide antibiotic, is valued for its efficacy against respiratory infections, Helicobacter pylori, and certain skin infections. It is available in diverse formulations, with a significant presence in both developed and emerging markets.

Major Suppliers

Global Patent Holders and Original Manufacturers:
- AbbVie Inc.: Historically held the patent and production rights before patent expiration, supplying clarithromycin in branded forms.
- Abbott Laboratories (now part of AbbVie): Developed early formulations, though market presence has shifted with generics.
Generic Manufacturers:
- Sun Pharmaceutical Industries (India): A leading generic supplier with high-volume API manufacturing capabilities for clarithromycin.
- Cipla: Provides affordable clarithromycin generics, with extensive API production and finished dosage formulations.
- Macleods Pharmaceuticals: An established supplier with significant API output for clarithromycin, primarily catering to emerging markets.
- Hetero Drugs: Active in both API manufacturing and finished formulations, reinforcing supply stability.
Chinese and Korean Firms:
- Shanghai Pharmaceutical and Daewoong Pharmaceutical: Significant suppliers within Asia, contributing to regional markets with exports expanding globally.

Supply Chain and Regulatory Aspects

The expiration of patents has enabled a proliferation of generics, increasing market competition and supply robustness.
API producers must navigate complex regulatory approvals, which are increasingly harmonized through initiatives like the International Council for Harmonisation (ICH).
Quality consistency remains key, with suppliers adhering to GMP standards and ensuring bioequivalence of finished products.

Vonoprazan Fumarate: Emerging Market and Key Suppliers

Market Overview

Vonoprazan fumarate is a novel potassium-competitive acid blocker (P-CAB), approved primarily in Japan for gastroesophageal reflux disease (GERD) and Helicobacter pylori infections. Its innovative mechanism offers advantages over traditional proton pump inhibitors (PPIs).

Leading Suppliers

Otsuka Pharmaceutical Co., Ltd. (Japan):
- Original Developer and Primary Supplier: As the pioneer and patent holder, Otsuka oversees all manufacturing and distribution of Vonoprazan Fumarate. Their strategic focus ensures controlled supply within Japan and potential global expansion.
Contract Development and Manufacturing Organizations (CDMOs):
- Taiwan Sembo Pharmaceutical Co., Ltd. and Suzhou Chia En Bio-Technology Co., Ltd.:
- Engage in contract manufacturing, aiding Otsuka in scaling production for international markets while maintaining proprietary control.
Potential Future Suppliers:
- As patent protections evolve, Chinese and Indian manufacturers are investing in R&D and API development for Vonoprazan fumarate, aiming to obtain regulatory approvals in other markets.

Supply & Regulatory Landscape

Japan’s complex regulatory environment confers control but limits immediate global availability.
Negotiations with regulatory authorities in the US (FDA), EU (EMA), and other regions are ongoing, seeking approvals to widen supplier base and distribution.
Patent protections and exclusivity periods influence the entry of generic suppliers, with implications for future supply stability and pricing.

Supply Chain Challenges and Opportunities

Regulatory Stringency: Ensures high-quality standards but can delay market entry for new suppliers.
Patent Lifecycle: Patent expirations for Amoxicillin and Clarithromycin open doors for generics, increasing supply options and competitive pricing.
Manufacturing Capacity: Capacity constraints and raw material availability may impact supply continuity, especially during global crises.
Quality Concerns: Suppliers must maintain consistent GMP standards to prevent delays and regulatory sanctions.
Market Dynamics: Increasing generic competition lowers prices, but also heightens procurement risks related to quality and supply stability.

Market Trends and Future Outlook

The expansion of API manufacturing capabilities in India and China will continue to diversify supply sources.
Regulatory harmonization and WHO prequalification programs are likely to facilitate broader access to quality-assured API supplies.
The evolving patent landscape of Vonoprazan Fumarate may catalyze new entrants, impacting supply stability and pricing.
Strategic procurement should prioritize diversified supplier bases, rigorous quality assessments, and proactive regulatory engagement.

Key Takeaways

Amoxicillin benefits from a mature, global supplier ecosystem dominated by Indian and Chinese manufacturers, ensuring supply resilience and cost competitiveness.
Clarithromycin has transitioned to a heavily genericized market, expanding supplier options and reducing reliance on original patent holders.
Vonoprazan Fumarate remains primarily supplied by Otsuka, with emerging opportunities for global suppliers as regulatory approvals expand.
Ensuring quality compliance and diversifying suppliers are critical strategies to mitigate risk and capitalize on market opportunities.
Monitoring patent expirations and regulatory developments will be crucial in forecasting future supply landscape shifts.

FAQs

1. Which are the top global manufacturers for Amoxicillin?
Major manufacturers include Pfizer, GlaxoSmithKline, Aurobindo Pharma, Hikma Pharmaceuticals, and Cipla, with Indian and Chinese producers significantly contributing to API supply.

2. How has patent expiry influenced Clarithromycin supply?
Patent expiration has led to a surge in generic manufacturers, increasing supply options and reducing prices while enhancing supply chain robustness.

3. What are the key considerations when sourcing Vonoprazan Fumarate?
Regulatory approval in target markets, patent status, manufacturing capacity, and quality assurance are critical factors influencing supply stability.

4. Are there quality concerns associated with API producers from emerging markets?
Ensuring GMP compliance and regulatory licensure mitigates quality risks; many Indian and Chinese producers meet international standards and are prequalified by global health agencies.

5. How might future regulations impact API supply chains?
Harmonized international standards and prequalification initiatives can streamline approvals, but increased scrutiny may also impose compliance challenges, affecting supply availability and costs.

References

[1] World Health Organization. (2020). WHO Model List of Essential Medicines.
[2] U.S. Food and Drug Administration. (2019). Guidance for Industry: Chemistry, Manufacturing, and Controls Changes to an Approved NDA or ANDA.
[3] European Medicines Agency. (2022). Guideline on the quality of Finished Products.
[4] GlobalData. (2023). Pharmaceutical API Market Analysis.

Suppliers and packagers for generic pharmaceutical drug: amoxicillin; clarithromycin; vonoprazan fumarate